We study the dynamics of three populations evolving in a two-dimensional discrete grid according to rules of attraction, rejection, or indifference following the framework of the seminal model by Sakoda and we apply it to migration phenomena. An interesting feature of the Sakoda model is the existence of a Potts-like energy which, as a common principle, decreases as time passes by. Here we consider the evolution of two populations until stabilization, then, we perturb this attractor by the inclusion of a third arrival: the immigrants. We show the conditions under which this irruption does not alter significantly the previous attractor (a sociological morphostatic behaviour) or it is dramatically changed (morphogenetic behaviour). We observe empirically that for a morphostatic behaviour the energy decreases while for morphogenesis this energy increases, revealing an escalation of social tension.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591578 | PMC |
http://dx.doi.org/10.1038/s41598-020-74805-3 | DOI Listing |
Oncologist
December 2024
Division of Geriatrics, University of California, San Francisco and San Francisco Veterans Affairs Health Care System, San Francisco, CA 94143, United States.
Introduction: Among older adults with cancer receiving chemotherapy, frailty indices predict OS and toxicity. Given the increased use of immunotherapy and targeted therapy for advanced non-small cell lung cancer (aNSCLC), we evaluated frailty and Karnofsky Performance Status (KPS) among older adults with aNSCLC receiving chemotherapy, immunotherapy, and/or targeted therapy.
Methods: Patients aged ≥ 65 with aNSCLC starting systemic therapy with non-curative intent underwent geriatric assessments over 6 months.
Am J Hum Genet
December 2024
Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Programs in Metabolism and Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
BMC Nephrol
October 2024
Center for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Aichi, Japan.
Epidemiology
January 2025
From the Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA.
Unlabelled: Cancer immunotherapy using immune checkpoint inhibitors and its combination with other anticancer therapies has emerged as a new standard of care because of the encouraging therapeutic effects in various solid cancers. Nonetheless, glioblastoma and pancreatic cancer remain resistant to immunotherapy and represent intractable cancers with the poorest prognosis. We investigated the therapeutic effects of next-generation chimeric antigen receptor (CAR) T cells producing IL7 and chemokine (C-C motif) ligand 19 (CCL19; referred to as 7 × 19 CAR-T) in these intractable cancers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!